Guggenheim Capital LLC Blueprint Medicines Corp Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

A detailed history of Guggenheim Capital LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Guggenheim Capital LLC holds 16,864 shares of BPMC stock, worth $1.53 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

16,864

Previous 12,298 37.13%

Holding current value

$1.53 Million

Previous $1.33 Million 17.66%

% of portfolio

0.01%

Previous 0.01%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$84.1 - $120.5 $384,000 - $550,203	4,566 Added 37.13%	16,864 $1.56 Million
Q2 2024 Aug 14, 2024	SELL	$85.18 - $108.78 $399,920 - $510,722	-4,695 Reduced 27.63%	12,298 $1.33 Million
Q1 2024 May 14, 2024	SELL	$73.17 - $99.79 $29,780 - $40,614	-407 Reduced 2.34%	16,993 $1.61 Million
Q4 2023 Feb 14, 2024	SELL	$43.96 - $92.84 $143,353 - $302,751	-3,261 Reduced 15.78%	17,400 $1.6 Million
Q3 2023 Nov 14, 2023	SELL	$46.9 - $66.0 $35,597 - $50,094	-759 Reduced 3.54%	20,661 $1.04 Million
Q2 2023 Aug 11, 2023	SELL	$42.2 - $66.37 $188,085 - $295,811	-4,457 Reduced 17.22%	21,420 $1.35 Million
Q1 2023 May 10, 2023	SELL	$37.97 - $50.0 $492,394 - $648,400	-12,968 Reduced 33.38%	25,877 $1.16 Million
Q4 2022 Feb 14, 2023	BUY	$41.06 - $66.48 $245,333 - $397,218	5,975 Added 18.18%	38,845 $1.7 Million
Q3 2022 Nov 14, 2022	SELL	$49.93 - $77.7 $315,258 - $490,597	-6,314 Reduced 16.11%	32,870 $2.17 Million
Q2 2022 Aug 15, 2022	BUY	$45.23 - $70.15 $28,133 - $43,633	622 Added 1.61%	39,184 $1.98 Million
Q1 2022 May 16, 2022	SELL	$54.1 - $110.08 $72,385 - $147,287	-1,338 Reduced 3.35%	38,562 $2.46 Million
Q4 2021 Feb 14, 2022	SELL	$94.25 - $115.99 $603,011 - $742,104	-6,398 Reduced 13.82%	39,900 $4.27 Million
Q3 2021 Nov 15, 2021	BUY	$80.98 - $109.47 $30,286 - $40,941	374 Added 0.81%	46,298 $4.76 Million
Q2 2021 Aug 13, 2021	BUY	$82.78 - $101.0 $768,281 - $937,381	9,281 Added 25.33%	45,924 $4.04 Million
Q1 2021 May 13, 2021	BUY	$90.71 - $108.28 $535,733 - $639,501	5,906 Added 19.21%	36,643 $3.56 Million
Q4 2020 Feb 16, 2021	BUY	$92.08 - $124.48 $1.93 Million - $2.61 Million	20,959 Added 214.35%	30,737 $3.45 Million
Q3 2020 Nov 13, 2020	BUY	$66.45 - $92.7 $4,585 - $6,396	69 Added 0.71%	9,778 $906,000
Q2 2020 Aug 14, 2020	SELL	$57.09 - $79.27 $1.62 Million - $2.24 Million	-28,313 Reduced 74.46%	9,709 $757,000
Q1 2020 Jun 02, 2020	SELL	$48.11 - $82.22 $199,319 - $340,637	-4,143 Reduced 9.83%	38,022 $2.22 Million
Q4 2019 Feb 14, 2020	BUY	$66.73 - $82.59 $2.81 Million - $3.48 Million	42,165 New	42,165 $3.38 Million
Q4 2018 Feb 14, 2019	SELL	$45.57 - $74.26 $2.16 Million - $3.52 Million	-47,412 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$58.91 - $78.32 $67,746 - $90,067	1,150 Added 2.49%	47,412 $3.7 Million
Q2 2018 Aug 14, 2018	BUY	$60.96 - $101.18 $360,334 - $598,074	5,911 Added 14.65%	46,262 $2.94 Million
Q1 2018 May 15, 2018	BUY	$73.28 - $102.95 $293,486 - $412,314	4,005 Added 11.02%	40,351 $3.7 Million
Q4 2017 Feb 14, 2018	BUY	$62.91 - $88.32 $2.29 Million - $3.21 Million	36,346	36,346 $2.74 Million

Others Institutions Holding BPMC

# of Institutions

351

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Blueprint Medicines Corp Transaction History